TB-500 Peptide: What It Is and How It Works

What Is TB-500?

TB-500 is a synthetic peptide built to copy the working part of thymosin beta-4, a small protein your body already makes in enormous quantities. Thymosin beta-4 shows up in nearly every cell and in the fluid around wounds, and its day job is managing actin, the protein scaffolding that lets cells hold their shape and physically move. When tissue is damaged, cells have to travel to the site to rebuild it. Thymosin beta-4 is a big part of what makes that travel possible.

The backstory runs through immunology. In the 1960s, Allan Goldstein and colleagues were isolating proteins from the thymus gland to understand immune function, and thymosin beta-4 came out of that work. The surprise arrived decades later: the molecule turned out to matter less for immunity than for repair. It binds actin, escorts repair cells to injuries, supports the growth of new blood vessels, and dials down inflammatory signaling. Goldstein himself summarized this second career in a 2005 review titled, fittingly, an actin-sequestering protein that moonlights to repair injured tissues.

Goldstein AL, Hannappel E, Kleinman HK, "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues," Trends in Molecular Medicine, 2005. Mechanistic review of the parent protein. View study

TB-500 exists because full thymosin beta-4 is a 43-amino-acid protein that is expensive to synthesize at scale. Most of its repair activity traces to one short stretch near the front of the molecule, the segment usually identified as amino acids 17 through 23, with the sequence LKKTETQ. That is the piece that grabs actin. TB-500 is a synthetic peptide built around that actin-binding segment: shorter, cheaper to make, and designed to keep the cell-migration activity of the parent. In practice, people use the names interchangeably. Chemically, they are not the same thing, and that difference matters more than most articles admit.

Is TB-500 the Same as Thymosin Beta-4?

No, and this is the single most useful thing to understand before reading anything else about TB-500, because nearly every impressive claim you will encounter borrows evidence from the parent molecule. Thymosin beta-4 is the full natural protein. It is the version that went through laboratory research, animal studies, and early-phase human clinical trials under the drug names RGN-137 and RGN-352. TB-500 is a fragment: a synthetic copy of the active region, sold by gray-market vendors and compounded by pharmacies, that has never been through a human trial of its own.

The fragment retains the actin-binding sequence, so the mechanistic logic carries over, and animal work on the isolated actin-binding domain supports its activity. But a seven-amino-acid core is not a 43-amino-acid protein, and honest accounting means saying so: when this article describes wound-healing trials or cardiac studies, that data belongs to full thymosin beta-4 unless stated otherwise. The regulatory picture reflects the same split. Neither molecule is an FDA-approved drug, and the full story of the trials, the pause in development, and where compounding law stands sits in our dedicated guide to whether TB-500 is FDA approved Read nextIs TB-500 FDA Approved? Parent in Phase 2 TrialsNo. TB-500 is not FDA-approved. But its parent molecule, Thymosin Beta-4, has been studied in multiple human clinical trials for wound healing and cardiac repair. RegeneRx Biopharmaceuticals ran these trials through Phase 2 before pausing development. TB-500 is the synthetic version used in compounded peptide therapy.Read article .

How Does TB-500 Work?

Most repair peptides are described in terms of what they signal. TB-500 is better described in terms of what it moves. Actin is one of the most abundant proteins in your body, the internal skeleton that cells constantly assemble and disassemble to crawl from one place to another. Thymosin beta-4 is the main protein that holds unpolymerized actin in reserve, keeping a ready pool that cells can draw on the moment they need to migrate. More available actin regulation means repair cells, the fibroblasts and endothelial and progenitor cells that rebuild tissue, can reach damage faster and start working sooner.

That is why TB-500 behaves differently from an injury-site peptide. It does not concentrate its effects where the needle goes. It circulates, and its influence shows up wherever cells are trying to move: healing tendons, remodeling blood vessels, closing wounds, calming inflamed tissue. Four downstream effects account for most of what the research describes.

A useful mental model: if BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide is a foreman directing construction at one job site, TB-500 is the highway system that gets workers to every site in the city. That framing also previews the pairing question below, and it explains why users describe TB-500 effects in whole-body terms, flexibility, general looseness, multiple old injuries quieting at once, rather than a single spot improving.

What Does the TB-500 Research Show?

Stated plainly: the TB-500 fragment has no published human trials. No dosing study, no safety trial, no efficacy trial. Everything meaningful in the literature was done on full thymosin beta-4, in animals and in a handful of early-phase human studies. That evidence is genuinely interesting, which is why the fragment became popular, but it transfers by inference, not by direct measurement. Here is what the parent-molecule record actually contains.

Wound healing is the anchor. In 1999, Malinda and colleagues showed that thymosin beta-4 applied to wounds in rats accelerated closure, increased new blood vessel growth, and sped the migration of keratinocytes, the cells that resurface a wound. This is the study that moved thymosin beta-4 from curiosity to drug candidate.

Malinda KM et al., "Thymosin beta4 accelerates wound healing," Journal of Investigative Dermatology, 1999. Rat wound model of the full protein. View study

The cardiac work made headlines. A 2004 study in Nature found that thymosin beta-4 promoted heart cell migration and survival in mice after cardiac injury, improving function afterward. It remains one of the most cited results in the field, it is also purely preclinical, and the injectable human cardiac program that followed was paused for funding reasons rather than completed.

Bock-Marquette I et al., "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair," Nature, 2004. Mouse model. View study

Human data exists, and it is early-phase. Treadwell and colleagues summarized the clinical program in 2012: in preclinical models and in patients with hard-to-heal wounds such as pressure ulcers and venous stasis ulcers, thymosin beta-4 accelerated dermal healing. These were small phase 2 trials of a topical gel, not injections, and they were conducted with the full protein. They are the closest thing TB-500 has to human evidence, and they are two steps removed from the product people actually inject.

Treadwell T et al., "The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients," Annals of the New York Academy of Sciences, 2012. View study

TB-500 Benefits: What the Evidence Supports

Benefit lists for TB-500 tend to be copied vendor to vendor without grades attached. The table below keeps the claims and adds the grades, because a benefit backed by a human trial of the parent protein and a benefit backed by forum posts are not the same kind of claim.

Reading that table honestly, the pattern is clear. The mechanism is real and well documented, the animal results are consistent across tissue types, and the human column is thin everywhere except topical wound care. People using TB-500 for a stubborn shoulder or chronically tight hamstrings are extrapolating, and reasonable people can decide that extrapolation is worth it, especially under provider screening. What nobody can honestly quote is a human response rate.

Why TB-500 Is Almost Always Paired With BPC-157

TB-500 rarely travels alone, and the reason is the mechanism split described above. BPC-157 acts strongest near the injection site, driving blood vessel growth and growth factor signaling right at the damage. TB-500 works everywhere at once, moving repair cells and calming inflammation system-wide. One is focal, one is systemic, and an injury needs both things to happen. Run together, the pair covers the specific problem and the environment it heals in. The combination is common enough that it earned a nickname, the Wolverine stack, which we unpack in our Wolverine stack guide Read nextWolverine Stack: BPC-157 and TB-500, ExplainedThe wolverine stack is two peptides, BPC-157 and TB-500, run together for injury recovery. This guide covers where the comic-book name came from, what each peptide contributes, what the research honestly supports, the side effects and open questions, what forum reports get right and wrong, and how the prescribed single-vial version differs from buying two research vials.Read article .

This site covers the pairing from several angles, so this section stays short. Why we pair BPC-157 with TB-500 Read nextWhy We Pair BPC-157 With TB-500BPC-157 and TB-500 are both repair peptides, but they cover different ground. BPC-157 works fast and focal, strongest at a specific injury and in the gut. TB-500 works broad and systemic, moving repair cells across the whole body. The pairing is not automatic. Here is how a provider decides whether you need both, or whether BPC-157 on its own does the job.Read article walks through which injuries call for one peptide and which call for both. BPC-157 vs TB-500 Read nextBPC-157 vs TB-500: What Is the Difference?Both are recovery peptides. Both are popular. But they work through completely different biological mechanisms. BPC-157 sends the repair signals. TB-500 moves the construction crew into position. Understanding the difference tells you which one you actually need, and whether combining them is worth it.Read article puts the two molecules side by side for anyone deciding between them. And the BPC/TB-500 combination guide Read nextBPC-157 and TB-500: Dosing and TimelineOne peptide sends the repair signals. The other moves the construction crew into position and builds the blood supply to keep them working. BPC-157 and TB-500 were discovered decades apart, on different continents, for completely different reasons. Practitioners started combining them because the science pointed to an obvious fit: they cover non-overlapping phases of the same healing process. This is the most widely used peptide combination in injury recovery.Read article covers the prescribed product itself, week-by-week expectations included. If TB-500 is the molecule that brought you here, know that at PeRx it is dispensed as half of that pair rather than on its own, for reasons the next sections make concrete.

TB-500 Side Effects and Unknowns

The honest framing first: with no human safety trials of the fragment, there is no measured side-effect rate for TB-500. What exists is the absence of documented serious harm in decades of parent-molecule research, the clean tolerability of the early thymosin beta-4 trials, and a large volume of informal user reports. That is reassuring but it is not a safety database, and anyone who tells you TB-500 is proven safe is overstating the file.

What users actually report is mild. Injection-site reactions lead the list: brief redness, a small welt, occasional soreness where the needle went in, all typical of any subcutaneous injection and handled by rotating sites. A short-lived head rush or lightheadedness after a dose appears in reports often enough to mention, and injecting while seated for the first week is a sensible habit. Temporary fatigue on injection days shows up occasionally in user accounts and has no controlled data behind it either way.

The unknowns deserve equal billing. Because TB-500 promotes cell migration and blood vessel growth, the same properties that make it interesting for repair raise a theoretical concern around cancer: a molecule that helps cells move and vessels grow is not something to take with an active malignancy. No human evidence shows TB-500 causes or accelerates cancer, and no evidence rules it out. This is precisely why the prescription route screens for cancer history before anything ships. Pregnancy and breastfeeding are excluded outright for lack of any data. And long-term use is uncharted territory, which is why prescribed protocols are cycled rather than continuous.

TB-500 Dosage Basics

Gray-market TB-500 dosing folklore involves loading phases, weekly milligram targets, and maintenance schedules, none of it anchored to human data, because no human dosing study of the fragment exists. The prescribed protocol through PeRx is simpler and bounded. The BPC/TB-500 Explore PeRxBPC/TB-500The Ultimate Recovery ComboView peptide vial is compounded at 3 mg of each peptide per mL, and the prescription is 20 units (0.2 mL) subcutaneously once daily, Monday through Friday, six weeks on and six weeks off. Each injection delivers 0.6 mg of TB-500 alongside 0.6 mg of BPC-157. The vial ships fully reconstituted and ready to use, so there is no mixing and no concentration math.

The numbers get their own treatments elsewhere: the TB-500 dosage guide Read nextTB-500 Dosage: Protocols, Units, Cycle LengthSearch for a TB-500 dosage and you get loading phases, maintenance weeks, and milligram figures that no human trial has ever tested. This page lays out where those numbers come from, why the clinical literature cannot settle them, and what the numbers look like when TB-500 arrives as a prescribed blend at a fixed concentration: 20 units on an insulin syringe, Monday through Friday, six weeks on and six off, as of September 8, 2026.Read article covers how prescribed dosing compares with the forum conventions, and the BPC-157/TB-500 dosage chart Read nextBPC-157/TB-500 Dosage Chart: Units, mg, CycleThe prescribed BPC-157/TB-500 blend has one concentration and one dose, and every number on this page follows from those two facts. Draw 20 units and you get 0.6 mg of each peptide. Here is the full arithmetic: the dosage chart, units on an insulin syringe, per-day and per-week totals, how the capsules dose differently, and what a month actually costs.Read article does the full units-to-milligrams arithmetic, vial math included. For placement, rotation, and technique, see where to inject TB-500 Read nextWhere to Inject TB-500: Sites and RotationTB-500 is a subcutaneous injection. One detail catches most people off guard: PeRx does not dispense TB-500 on its own. It comes pre-mixed with BPC-157 in a single ready-to-use vial, so "where to inject TB-500" is really "where to inject the BPC-157/TB-500 combo." The four standard subQ sites all work, and because this is a tissue-repair combination, there is a practical case for injecting near the injury when it makes sense. Here is the guide patients ask for after their first vial arrives.Read article . Your PeRx provider prescribes the protocol, and the label on your vial is the final word.

How to Get TB-500

Two routes exist, and they are different in kind. Research-chemical websites sell TB-500 powder labeled not for human use, with no prescription, no screening, and no verification of what the vial contains or whether it is the fragment, the full protein, or neither. The prescription route runs the opposite way: a licensed provider reviews your health history, screens for the exclusions above, and if appropriate sends a prescription to a US 503A compounding pharmacy, which dispenses a labeled product. The gap between those two supply chains is the subject of our guide to research peptides vs prescription peptides Read nextResearch Peptides vs Prescription Peptides (2026)An honest comparison for the patient who already uses peptides, what the 'Not for Human Use' label actually means, the real quality differences, and the practical steps to switch from research-chemical sourcing to a prescription supply.Read article .

One thing to know before you look for a standalone vial here: PeRx does not sell one. TB-500 is dispensed only inside combination products, because the clinical reasoning runs pairing-first. A systemic migration peptide with no local repair signal is half a protocol, so the prescribed formats build the pairing in. There are three.

BPC/TB-500

The core format: 3 mg of BPC-157 and 3 mg of TB-500 per mL in a single 5 mL vial, compounded by a US 503A pharmacy and third-party tested. One daily subcutaneous injection covers the local repair signal and the systemic one at once. It ships fully reconstituted and ready to use, refrigerated, with insulin syringes and an injection guide in the box.

From $299 for a one-month supply, prescribed after provider review of your intake. Your card is charged only if a provider approves the prescription.

Physician-screened, pharmacy-compounded, shipped ready to use.

Shop Now

BPC/TB-500 Capsules

The same pairing in a needle-free format: 500 mcg of each peptide in a once-daily oral capsule. Capsules trade injection logistics for convenience, travel easily, need no refrigeration, and suit people whose goals lean toward gut support and general recovery rather than a single acute injury.

From $225 for 30 capsules. Some patients also use capsules to continue support between injection cycles, a call your reviewing provider makes on your prescription.

The recovery pairing in a once-daily oral capsule.

Shop Now

The third format is KLOW, a four-peptide blend that adds GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide and KPV to the BPC-157/TB-500 pair for people juggling recovery alongside skin and inflammation goals, at $349 per month. Our KLOW guide Read nextKLOW Peptide: The Complete GuideKLOW packs four repair peptides into one prescribed vial: BPC-157, GHK-Cu, KPV, and TB-500. This guide covers what each one contributes, what the research actually supports, what a six-week cycle looks like in practice, and how the prescribed vial differs from the research-site blends that dominate search results.Read article covers when the four-peptide version earns its place over the pair. Whichever format fits, the process is the same: complete the online intake, a licensed provider reviews it, and if approved the pharmacy ships overnight in refrigerated packaging with everything needed to start.

TB-500: Common Questions